SINOVAC
4.7.2022 13:32:06 CEST | Business Wire | Press release
A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific COVID-19 inactivated vaccine used as a booster shot in healthy adults, in anticipation of providing scientific evidence for future immunization strategy. This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005146/en/
In this study, a total of 300 healthy adult volunteers aged 18 and above who have been vaccinated with two or three doses of inactivated or mRNA COVID-19 vaccine will be recruited.
“As we know, vaccination is one of the most effective ways to cope with infectious diseases. Currently, Omicron continuously sweeps the world. I hope the clinical trial could strengthen and effectively promote vaccine research and vaccination administration,” Professor Ivan Hung Fan-ngai, Ru Chien & Helen Lieh Professor in Health Sciences Pedagogy, Clinical Professor and Chief of Infectious Diseases, and Assistant Dean of Department of Medicine, School of Clinical Medicine, Assistant Dean (Admissions), LKS Faculty of Medicine, The University of Hong Kong (HKUMed), stated in the ceremony.
“As one of the research sites of HKU, we are pleased to be part of this clinical trial project and contribute to the continuous research and development of vaccines and immunization strategies to help enhance health protection for people,” said Dr Kenneth Tsang.
“It is of great significance to cooperate with Professor Hung, HKU-CTC and Gleneagles to carry out the clinical trial of the COVID-19 inactivated vaccine as a booster shot against the Omicron strain. We hope to find a solution for Hong Kong and the globe to fight against the new viruses with the results of this trial,” said Ms. Cheryl Law, International Business Development Director of SINOVAC.
SINOVAC obtained the sample of the Omicron variant in early December 2021 and then actively promoted research and development of its inactivated COVID-19 vaccine (Omicron specific strain). Preclinical research demonstrated that the vaccine is safe and effective in animals. The Omicron strain booster immunization clinical trial was then approved by the HKU GHK Institutional Review Board (IRB) on 12th April 22 and by the Pharmacy and Poisons Board of Hong Kong on 14th April 22, allowing the carrying out of the clinical study on boosting the immunity of people against the new coronavirus strain in Hong Kong.
About Sinovac Biotech Ltd.
SINOVAC Biotech Ltd. (SINOVAC) is a China-based leading biopharmaceutical company that focuses on the research, innovation, manufacture, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against emerging infectious diseases such as COVID-19, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and enterovirus 71 (EV71), and other common infectious diseases such as viral hepatitis, seasonal influenza, pneumococcal pneumonia, poliomyelitis, varicella and mumps. SINOVAC is also exploring opportunities in the international market and is exporting it vaccines to tens of countries and international organizations. More information about SINOVAC can be found at www.sinovac.com .
About HKU Clinical Trials Centre
The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed. Since its establishment, HKU-CTC has already facilitated over a thousand of sponsored clinical studies and investigator-initiated clinical studies in collaboration with sponsors and investigators around the world.
About Gleneagles Hospital Hong Kong
Located at Wong Chuk Hang on Hong Kong Island South, Gleneagles Hospital Hong Kong (Gleneagles) is a multi-specialty private hospital, providing 500 beds, cutting-edge medical technologies and a comprehensive range of clinical services spanning more than 35 specialties and subspecialties. As Hong Kong’s top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research. Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner. More information on Gleneagles Hospital Hong Kong can be found at https://www.gleneagles.hk/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005146/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB OneSubsea Awarded Integrated EPC Contract for Deepwater Development17.3.2026 13:30:00 CET | Press release
Award adds to OneSubsea’s project pipeline and reinforces its standardized system design Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a multi-well, integrated engineering, production, and construction (EPC) contract by China National Offshore Oil Corporation (CNOOC). The contract encompasses 20 wells and covers the delivery of integrated subsea production systems for the deepwater Kaiping 18-1 field development in the South China Sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317076557/en/ SLB OneSubsea will deliver standardized subsea production technology that includes dual electric submersible pump (ESP), gas lift and gas injection horizontal trees, manifolds, connectors, and control systems, along with installation and commissioning support. Under the contract, SLB OneSubsea will deliver standardized subsea production technology that includes
HyperLight Introduces 400G-per-lane TFLN PICs on its Chiplet™ Platform for Next-Generation AI Interconnects17.3.2026 13:03:00 CET | Press release
HyperLight Corporation (“HyperLight”), creator of the TFLN Chiplet™ Platform, today announced the availability of 400G-per-lane thin-film lithium niobate (TFLN) photonic integrated circuits (PICs) designed for next-generation AI networking infrastructure. The new PIC family delivers low insertion loss, low drive voltage operation, and exceptional electro-optic bandwidth, enabling energy-efficient and high-performance 400G-per-lane optical links. The transition to 400G-per-lane is a critical step for future AI infrastructure, enabling higher interconnect bandwidth and improved system density. HyperLight’s 400G-per-lane TFLN PICs provide the large electro-optic bandwidth and low-voltage operation required to support these next-generation optical links, where bandwidth, signal integrity, and power efficiency are increasingly challenging for electronic ICs to sustain. HyperLight’s TFLN devices combine high modulation efficiency with extremely low optical loss, enabling transmitter architec
Klarna Smashes 1 Million Merchants Milestone17.3.2026 13:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, has surpassed 1 million merchants globally. Klarna has grown the number of merchants offering its payment methods by 47% in the past year, adding 285,000 merchants in 2025, and more than 115,000 in the final quarter alone. The growth is being driven by Klarna's expanding agreements with the world's leading payment service providers, giving merchants around the world easier access to Klarna at checkout. Leisure, Sport & Hobby is now Klarna's fastest-growing merchant category, up 91% YoY in February 2026, reflecting growing consumer demand for flexible payments in wellness and fitness. David Sykes, Chief Commercial Officer at Klarna: "Home repairs, a new couch, salon appointments, gym memberships - these are facts of life for most people, but the way they pay for them hasn't kept up. Reaching 1 million merchants is a reflection of how deeply embedded Klarna is becoming in everyday money management, and the acceleration acros
Armis Warns Cyberwarfare Threats at Global Tipping Point as AI Accelerates Escalation17.3.2026 13:00:00 CET | Press release
65% of IT decision-makers believe the convergence of AI, quantum, and emerging technologies will drive unprecedented escalation in cyber conflict Half of respondents say cyberwarfare threat is imminent and have had to report an act of cyberwarfare to authorities Armis, the cyber exposure management & security company, is warning that cyberwarfare threats have reached a global pressure-cooker moment. As emerging technologies accelerate cyber operations and geopolitical tensions worsen, attackers are increasingly targeting the infrastructure, information, and systems that underpin global stability. “Geopolitical tensions, AI acceleration, and unresolved security gaps are colliding, bringing the state of cyberwarfare to a boiling point,” said Nadir Izrael, CTO and Co-Founder of Armis. “Cyberwarfare is now a constant condition; attackers are operating at machine speed, while too many organizations are still trying to defend themselves with assumptions and structures built for a very differ
1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates17.3.2026 13:00:00 CET | Press release
Fifth edition of Hologic Global Women’s Health Index reveals over half of women worldwide weren’t tested for key conditions in the past yearHologic and Gallup convene experts to discuss closing gaps in screening access Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today released data showing that while testing for some health conditions has risen among women globally, a vast screening gap remains. Over half of women and girls aged 15 and older — an estimated 1.5 billion women — were not tested for cancer, high blood pressure, diabetes or sexually transmitted infections (STIs) in the past year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317786907/en/ Hologic Global Women's Health Index Fifth Edition The data are part of the fifth edition of the Hologic Global Women’s Health Index developed in partnership with Gallup. Based on an annual survey of 145,000 people in 144 countries and territories, the Index tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom